9月，随着传统旺季的到来，医药行业供给增速有所回升，其中，中成药产量环比增长17.96%，化学原料药产量环比增长4.49%，中西药品类零售总额环比增长15.0%。在

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面对医药行业进行了分析评论。

报告从产业动态、产业分析、技术趋势、企业跟踪、地方动向等几个方面对生物科技产业进行了分析评论。

This report covers the present scenario and the growth prospects of the Global Tissue Diagnostics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of tissue diagnostics technologies and products including instruments and consumables. The predominant technologies used in tissue diagnostics are IHC, ISH, Digital Pathology, and Special Staining. In addition, the report includes the revenue generated from the use of tissue diagnostics for the diagnosis of different types of diseases.

pH范围习惯上是0～14,这是以水的解离性质为基础的。然而,在某些情况下,水的含量有可能大大降低,或者被另一种溶剂所代替,此时,溶剂的电离平衡与水不同,它取决于不同溶剂的自身离解常数（Ks）,在25℃时,水的Ks=1×10-14,乙醇的Ks=7.9×10-20。在胰岛素的生产过程中,需用60～80％的乙醇溶液提取,乙醇和胰腺中高级脂肪酸物质的存在均能影响提取液pH值的检测。

目的探讨中药甘遂所致小鼠肝脏氧化损伤的作用机制。方法昆明种小鼠40只,雌雄各半,随机分为4组,分别为4g/kg组(1/8 LD50)、2 g/kg组(1/16 LD50)、1 g/kg组(1/32 LD50)及正常对照组,连续灌胃给药21 d后测定小鼠体质量及肝脏脏器系数;HE染色观察各组小鼠肝组织形态学变化;紫外分光光度法测定各组小鼠血清谷丙转氨酶（alanine amiotransferase,ALT）、谷草转氨酶（aspartate aminotransferase,AST）酶活性;肝组织超氧化物歧化酶（superoxide dismutase,SOD）、谷胱甘肽过氧化物酶（glutathione peroxidases,GSH-Px）水平,丙二醛（malondialdehyde,MDA）、超氧阴离子自由基（O2-·）、羟自由基（OH·）含量的变化,流式细胞仪检测肝细胞内活性氧（reactive oxygen species,ROS）的变化。结果随着甘遂剂量增加,小鼠体质量明显下降,肝脏脏器系数显著升高（P<0.05）;血清ALT和AST活性显著升高（P<0.05）;肝组织SOD、GSH-Px活性显著降低（P<0.05）、MDA含量显著升高（P<0.05）;肝组织氧自由基O2-、OH·、ROS含量显著增高（P<0.05）。结论甘遂通过脂质过氧化作用而引起肝损伤。

This chapter deals with the problem of fitting curves to data points, a classical optimization problem in Computer-Aided Geometric Design (CAGD). This issue plays an important role in real problems such as construction of car bodies, ship hulls, airplane fuselage, and other free-form objects. A typical example comes from reverse engineering where free-form shapes are extracted from clouds of scanned data points. In this chapter we address this issue by applying a powerful bio-inspired method called Artificial Immune Systems (AIS). The AIS can be understood as a computational methodology based upon metaphors of the biological immune system. As such, there is not one but several AIS algorithms. In this chapter we focus on the clonal selection algorithm (CSA), which explicitly takes into account the affinity maturation of the immune response. This algorithm is applied to fit Bezier curves to given sets of data points. Some illustrative examples show the good performance of our approach.

Our initial hypothesis was that chimeric antigen receptor (CAR)- based immunotherapy of epithelial ovarian carcinoma (EOC) could be potentiated by depletion of tumor-associated macrophages (TAM). To test this, we engineered T-cells to express CARs with specificity for MUC1 (expressed by tumor cells) and CSF-1R (expressed both by tumor cells and TAM). In-vitro experiments demonstrated some efficacy of this approach but significant anti-tumor activity could not be confirmed in-vivo. Consequently, a revised statement of work was agreed in which CAR-mediated targeting of ErbB receptors by EOC tumor cells was pursued instead. A CAR termed T1E28z was engineered which engages several ErbB receptor dimers that are upregulated in EOC. Liposomal clodronate was used to achieve depletion of TAM. T1E28z-transduced T-cells proved effective in killing both autologus patient-derived tumor cell cultures and EOC cell lines (IGROV-1 and SKOV-3) in-vitro. Using bioluminescence imaging (BLI), we then demonstrated that T1E28z+ T-cells mediated the regression of established intraperitoneal SKOV-luc tumors in SCID Beige mice. Highly efficient depletion of TAM was achieved using liposomal clodronate. However, this did not influence anti-tumor activity and appeared to reduced efficacy somewhat. To monitor Tcell persistence in this model, renilla luciferase was co-expressed in T1E28z+ T- cells. This analysis revealed that T-cells undergo progressive decline in tumor- bearing mice, providing a rationale for repeated T-cell administration. In support of this, we found that dual dosing with T1E28z+ T-cells enhanced therapeutic efficacy in this model. Bridging the gap to clinical implementation, proof of concept was also demonstrated for the use of the human sodium iodide symporter (hNIS) as a clinically applicable imaging reporter of T-cell location. We provide evidence that administration of 99mTc-pertechnetate enables the serial real-time tracking of T1E28z/hNIS+ T-cells in-vivo, using SPECT-CT.